This study has involved the design, synthesis and evaluation of novel HIV-1 enzyme inhibitors accessed by synthetic elaboration of Baylis-Hillman adducts. Several series of complex coumarin-AZT and cinnamate ester-AZT conjugates have been prepared, in high yields, by exploiting the click reaction between appropriate Baylis-Hillman derived precursors and azidothymidine (AZT), all of which have been fully characterised using spectroscopic techniques. These conjugates, designed as potential dual-action HIV-1 inhibitors, were tested against the appropriate HIV-1 enzymes, i.e. HIV-1 reverse transcriptase and protease or HIV-1 reverse transcriptase and integrase. A number of the ligands have exhibited % inhibition levels and IC50 values comparable to drugs in clinical use, permitting their identification as lead compounds for the development of novel dual-action inhibitors. In silico docking of selected ligands into the active sites of the respective enzymes has provided useful insight into binding conformations and potential hydrogen-bonding interactions with active-site amino acid residues. A series of furocoumarin carboxamide derivatives have been synthesised in four steps starting from resorcinol and these compounds have also been tested for HIV-1 integrase inhibition activity. The structures of unexpected products isolated from Aza-Baylis-Hillman reactions of N-tosylaldimines have been elucidated by spectroscopic analysis, and confirmed by single crystal X-ray analysis. A mechanism for what appears to be an unprecedented transformation has been proposed. Microwave-assisted SeO₂ oxidation of Baylis-Hillman-derived 3-methylcoumarins has provided convenient and efficient access to coumarin-3-carbaldehydes, and a pilot study has revealed the potential of these coumarin-3-carbaldehydes as scaffolds for the construction of tricyclic compounds. The HCl-catalysed reaction of tert-butyl acrylate derived Baylis-Hillman adducts has been shown to afford 3-(chloromethyl)coumarins and α-(chloromethyl)cinnamic acids, the Zstereochemistry of the latter being established by X-ray crystallography. ¹H NMR-based experimental kinetic and DFT-level theoretical studies have been undertaken to establish the reaction sequence and other mechanistic details. Base-catalysed cyclisation on the other hand, has been shown to afford 2H-chromene rather than coumarin derivatives.

Polycyclic aromatic hydrocarbons, produced by anthropological and natural activities, are hazardous through formation of oxidative radicals and DNA adducts. Growth of Mycobacterium sp. strain KMS, isolated from a contaminated soil, on the model hydrocarbon pyrene induced specific proteins. My work extends the study of isolate KMS to the gene level to understand the pathways and regulation of pyrene utilization. Genes encoding pyrene-induced proteins were clustered on a 72 kb section on the KMS chromosome but some also were duplicated on plasmids. Skewed GC content and presence of integrase and transposase genes suggested horizontal transfer of pyrene-degrading gene islands that also were found with high conservation in five other pyrene-degrading Mycobacterium isolates. Transcript analysis found both plasmid and chromosomal genes were induced by pyrene. These processes may enhance the survival of KMS in hydrocarbon-contaminated soils when other carbon sources are limited. KMS also grew on benzoate, confirming the functionality of an operon containing genes distinct from those in other benzoate-degrading bacteria. Growth on benzoate but not on pyrene induced a gene, benA, encoding a benzoate dioxygenase α-subunit, but not the pyrene-induced nidA encoding a pyrene dioxygenase α-subunit; the differential induction correlated with differences in promoter sequences. Diauxic growth occurred when pyrene cultures were amended with benzoate or acetate, succinate, or fructose, and paralleled delayed expression of nidA. Single phase growth and normal expression of benA was observed for benzoate single and mixed cultures. The nidA promoters had potential cAMP-CRP binding sites, suggesting that cAMP could be involved in carbon repression of pyrene metabolism. Growth on benzoate and pyrene requires gluconeogenesis. Intermediary metabolism in isolate KMS involves expression from genes encoding a novel malate:quinone oxidoreductase and glyoxylate shunt enzymes. Generation of C3 structures involves transcription of genes encoding malic enzyme, phosphoenolpyruvate carboxykinase, and phosphoenolpyruvate synthase. Carbon source modified the transcription patterns for these genes. My findings are the first to show duplication of pyrene-degrading genes on the chromosome and plasmids in Mycobacterium isolates and expression from a unique benzoate-degrading operon. I clarified the routes for intermediary metabolism leading to gluconeogenesis and established a potential role for cAMP-mediated catabolite repression of pyrene utilization.

It has been found in previous studies that there is a correlation between the placenta regulatory genes and the weight gain of the mother, Body Mass Index (BMI) as well as the birthweight of the fetus. When the mother gains weight / is overweight, this will affect the gene expression in the placenta, and in turn this triggers the weight gain of the fetus. The aim of the study was to investigate the correlation between the lipoprotein lipase gene and the mother's BMI, weight gain and the child's birth weight by extracting RNA from the placentas and analysing its quality and concentration. cDNA was generated from RNA using reverse transcription and gene expression was amplified using real-time PCR. The data from real-time PCR was used in the comparative Ct-method to calculate a 2˄(-ΔΔCt)-value which represents the RNA-level of the LPL-gene. Lastly this value was analysed by using the two-statistic methods, Pearson's rank correlation and Spearman's correlation, which showed that the value of the correlation coefficient for all the variables was close to the value of zero. The closer the value is to zero, the weaker the association becomes between the different variables. The correlation was 0.045, 0.112 and 0.044 for the child's birth weight, mother's BMI respective weight gain. The results from this study shows that there is no correlation between LPL and the mother's weight gain, BMI, or the child's birth weight.

No description available.

The use of a surface plasmon biosensor fills a missing link in kinetic studies of enzymes, since it measures directly the interaction between biomolecules and allows determination of parameters that are determined only indirectly in activity assays. The present thesis deals with kinetic and dynamic aspects of ligand binding to two viral enzymes: the human cytomegalovirus (HCMV) protease and the human immunodeficiency virus type 1 reverse transcriptase (HIV-1 RT). The improved description of interactions presented herein will contribute to the discovery and development of antiviral drugs. The biosensor method provided new insights into the interaction between serine proteases and a peptide substrate, as well as substrate-induced conformational changes of the enzymes. The direct binding assay served as a tool for characterising the binding mechanism of HCMV protease inhibitors. Kinetic details of the interaction between HIV-1 RT and non-nucleoside reverse transcriptase inhibitors (NNRTIs) were unravelled. The recorded sensorgrams revealed several forms of complexity. A general binding model for the analysis was derived from the data, describing a two-state mechanism for the enzyme and a high- and a low-affinity interaction with the inhibitor. Interaction kinetic constants were determined for the clinically used NNRTIs and several investigational inhibitors. The established method was applied to investigate the mechanism of resistance against NNRTIs. Amino acid substitutions in the NNRTI-binding site resulted in both decreased association rates and increased dissociation rates for the inhibitors. The K103N and the L100I substitution also interfered with the formation of the binding site, thereby facilitating inhibitor binding and unbinding. Finally, thermodynamic analysis revealed that, despite the hydrophobic character of the interaction, NNRTI binding was mainly enthalpy-driven at equilibrium. Large entropy contributions in the association and dissociation indicated that binding is associated with a dynamic effect in the enzyme.

Les virus de l'Immunodéficience Humaine de type 1 et 2 (HIV-1 et HIV-2) et de l'Hépatite B (HBV) représentent un intérêt particulier en santé publique. En effet, on estime à plus de 33 millions le nombre de personnes infectées par le virus HIV dans le monde et 360 millions par HBV. La transcriptase inverse (RT) est une enzyme nécessaire à leur réplication et constitue donc une cible majeure des drogues antivirales. Parmi les NRTI commercialisés, les analogues de nucleotides de type phosphonates acyclique, comme l'Adefovir (HEPSERA®, Gilead) et le Tenofovir (VIREAD®, Gilead) sous forme prodrogue, ont révolutionné les traitements contre les virus HBV et HIV. Devant l'emmergence de virus résistants, il est urgent de développer de nouveaux antiviraux plus puissants et surtout actifs sur ces souches afin d'optimiser les multithérapies antivirales. Dans ce but, nous avons conçu des analogues thiophosphonates dérivés de l'Adefovir (PMEA) et du Tenofovir (PMPA), non toxiques pour la cellules et actifs contre HIV-1, HIV-2 et HBV en culture de cellules infectées. Ces composés, baptisés Adethiovir et Tenothiovir, ont été synthétisés selon une méthode originale et ont fait l'objet d'un dépôt de brevet. Nous avons synthétisé les formes diphosphates correspondantes : incorporés par la RT, terminateurs de chaîne, ils contournent la résistance associée au mutant K65R. Notre objectif est donc de les pousser plus loin dans le « pipe-line » du développement de médicaments antiviraux. / The Human Immunodeficiency Virus type 1 and type 2 (HIV-1 and HIV-2) and Hepatitis B (HBV) constitue a special interest in public health. Indeed, it is estimated that more than 33 million people infected with HIV worldwide and 360 million with HBV. Reverse transcriptase (RT) is an enzyme required for their replication and is therefore a key target for antiviral drugs. Among the NRTI marketed, nucleotide analogues like acyclic phosphonates, such as adefovir (Hepsera ®, Gilead) and Tenofovir (VIREAD ®, Gilead) as a prodrug form, have revolutionized the treatment against HBV and HIV. With the emmergence of resistant virus, there is a need to develop new antiviral compounds that are targetting especially these to optimize antiviral combination therapies. For this purpose, we designed analogues thiophosphonates derivatives Adefovir (PMEA) and tenofovir (PMPA), that are non-toxic in cells and active against HIV-1, HBV and HIV-2 infected cell cultures. These compounds, named Adethiovir Tenothiovir, were synthesized according to an original method and were the subject of a patent. We synthesized the corresponding diphosphates forms: incorporated by RT, chain terminators, they bypass the resistance associated with the K65R mutant. Our goal is to push them further in the "pipeline" development of antiviral drugs.

O câncer de mama em mulheres jovens (idade igual ou abaixo de 35 anos) apresenta-se de forma mais avançada ao diagnóstico, possuindo grau histopatológico menos diferenciado. Além disso, as pacientes apresentam maior taxa de mortalidade e menor sobrevida livre de doença quando comparadas às pacientes menopausadas. Dentre os cânceres de mama em mulheres jovens, apenas 8 a 10% dos casos familiais estão relacionados a mutações nos genes BRCA1 e BRCA2 e esta frequência nos casos esporádicos é ainda menor (3- 10%). Assim, os fatores relacionados à desregulação oncogênica em mulheres jovens com ou sem antecedentes familiares que apresentam testes genéticos negativos para essas mutações não estão suficientemente esclarecidos. Tais evidências sugerem que o câncer em mulheres muito jovens apresenta características biológicas especificas. Considerando que a expressão gênica é regulada em múltiplos níveis, alguns estudos recentes tem referido a importância dos microRNAs neste processo tanto na degradação de RNAs mensageiros como na repressão da tradução. A análise da expressão dos microRNAs em câncer de mama tem revelado perfis característicos de determinados níveis de progressão da doença. No presente trabalho, nosso objetivo foi determinar o perfil de expressão de microRNAs em tumores de mama de mulheres jovens (idade igual ou abaixo de 35 anos) não-portadoras de mutações nos genes BRCA1/2. As pacientes foram subdivididas em 2 grupos [familial (n=8) e não-familial (n=20)] e, em seguida, os dados de expressão foram comparados aos obtidos em amostras normais de mamoplastia. A quantificação da expressão dos microRNAs foi realizada pela reação de RT-PCR em tempo real, utilizando o sistema TaqMan microRNA Assay. As análises estatísticas mostraram 246 miRNAs de expressão diferencial entre os 3 grupos (normal, familial e não-familial) sendo que, destes, encontramos 137 miRNAs diferencialmente expressos entre os grupos familial e normal; 44 miRNAs entre os grupos não-familial e normal e 4 miRNAs entre os grupos familial e não-familial. Nossos dados demonstram que os tumores do grupo de pacientes familiais quando comparados aos normais apresentam um perfil de miRNAs globalmente reduzido. O perfil de expressão de miRNAs no grupo de pacientes com câncer de mama esporádico é pouco distinto do grupo com história familial. Muitos dos miRNAs com expressão reduzida estavam envolvidos, de acordo com a literatura, numa sinalização comum relacionada a mecanismos de proliferação, apoptose e invasão celular. Os 4 miRNAs identificados como diferencialmente expressos entre os grupos familial e nãofamilial embora relacionados com outros tipos de cancer precisam de uma melhor caracterização em cancer de mama / A rise in the incidence of breast cancer among young adult women (with age 35) was observed in recent decades. Breast cancer incidence in young woman has been correlated to poor survival and aggressive features. Due to different type of breast cancers in young woman, 8- 10% with familial history appears with mutation in BRCA1/2 genes, and similar proportion occurs in cases without familial history (3- 10%). However, early onset breast cancer patients with or without familial history, non carriers of BRCA1/BRCA2 mutations is not well elucidated. The deregulation by microRNAs has recently emerged as a major determinant of tumorigenesis. Because miRNAs function by targeting functionally important protein-conding genes, it is of outstanding interest to identify miRNAs involved in the molecular mechanism underlying aggressiveness in tumors of young patients that might represent biomarkers and therapeutic targets. This evidence suggests that breast cancer in young woman has specific biological characteristics. Understanding the patterns of miRNAs expression that potentially alter the regulation of key breast cancer genes we could give a better treatment to these patients. Thirty-two patients were selected: 8 with familial history of breast and ovarian suggestive of hereditary condition according to NCCN criteria and 20 without familial history. Patients of both groups were of non carriers of BRCA1/BRCA2 mutations. The determination of microRNA expression network between those 2 groups was performed by TaqMan microRNA Assay (Applied Biosystems) using as control 3 normal mamoplastia samples from wealthy young women. Data were normalized using endogenous miRNA presented in each array. Statistical comparisons were done using ANOVA and Student T test with adjusted FDR (5%). It was found that 246 miRNAs were differently expressed between the 3 groups. From the comparison of familial group against normal group it was found 137 miRNAs differently expressed. In the comparison between non familial and normal group it was found 44 miRNAs differently expressed. Finally the comparison between familial group and non familial group it was found 4 miRNAs differently expressed. Among these miRNAs are some which was well characterized in breast cancer with down-regulation such as: miR-125b, miR-126 and miR-100. Our findings suggested that tumors from familial or sporadic cases presented discrete differences of microRNA expression patterns. A global downregulation of 137 miRNAs in tumors from familial group of patients when compared to normal group was observed. Based on the literature, most of these miRNAs are related to mechanisms of proliferation, cells migration and apoptosis. To our knowledge, this is the first evidence of miRNA expression in tumors of early onset Breast Cancer patients, non carries BRCA1/2 mutation, providing insights that may lead to the detection of new conducts of treatment

O câncer de mama é a doença maligna mais comum e a principal causa de morte entre as mulheres. Sua complexa etiologia envolve múltiplos fatores de risco, a maioria deles relacionada aos níveis cumulativos de exposição da mama aos estrógenos. A maioria de suas ações é mediada pela ligação a seus receptores ER e ER que são fatores de transcrição. Outro fator que exerce um controle extraordinário no comportamento celular, regulando a transcrição gênica e influenciando diversos processos biológicos, e que, quando alterado, é associado ao processo de tumorigênese da mama é a matriz extracelular. A laminina, um dos principais componentes da matriz extracelular, interage com as células através das integrinas e está relacionada ao fenótipo maligno, atuando na adesão, migração, proliferação, diferenciação e sobrevivência celular. Nosso grupo identificou diversos genes diferencialmente expressos em células de câncer de mama ER+ na presença ou ausência de uma monocamada de laminina utilizando a técnica DDRT-PCR. Dois dos genes identificados, DDEF2 e PHLDA1, estão associados à adesão; DDEF2 envolvido na sinalização das integrinas e PHLDA1 relacionado com apoptose por perda de adesão. Nosso objetivo foi investigar os efeitos do 17-estradiol e da laminina na regulação da expressão dos genes DDEF2 e PHLDA1 nas linhagens celulares MCF-7, MDA-MB-231 e posteriormente S30, utilizando a técnica RT-PCR em tempo real. O gene PHLDA1 foi induzido pelo E2 via ER nas células MCF-7 e pela laminina nas células S30, e o gene DDEF2 foi reprimido pelo E2 e induzido pela laminina nas células S30 / The breast cancer is the most common malignant disease and the leading cause of death among women. Its complex etiology involves multiple risk factors, most of them related to the levels of cumulative breast exposure to estrogen. Most of its actions is mediated by binding to its receptor ER and ER that are transcription factors. Another factor that has a tremendous control in cell behavior, regulating the gene transcription and influencing various biological processes, which when altered, is attached to the process of tumorigênese of the breast is the extracellular matrix (ECM). The laminin, one of the main components of the ECM, interacts with the cells through integrins and is related to the malignant phenotype, acting in adhesion, migration, proliferation, differentiation and cell survival. Our group identified several genes diferentialy expressed in breast cancer cells ER + in the presence or absence of a laminin monolayer using the technique DDRT-PCR. Two of the genes identified, DDEF2 and PHLDA1, are associated with adhesion; DDEF2 is involved in the integrins signaling and PHLDA1 is related with apoptosis by loss of adhesion. Our goal was to investigate the effects of 17-estradiol and laminin in regulating the expression of the genes DDEF2 and PHLDA1 in MCF-7, MDA-MB-231 and later S30 cell lines, using the real time RT-PCR technique. The gene PHLDA1 was induced by E2 via ER in MCF-7 cells and the laminin in S30 cells, and the gene DDEF2 was suppressed by E2 and induced by laminin in S30 cells

<p>Reverse transcriptase (RT) is a crucial enzyme for retrovirus replication, and its presence in the virion is indispensable for infectivity. This thesis illustrates the use of RT activity assays as tools for quantitation and characterization of different retroviruses, particularly HIV. </p><p>A non radioactive assay, using microtiter plates, for the RT of Moloney murine leukemia virus (MMuLV) was developed. Assay conditions for MMuLV and HIV-1 RT, together with isozyme specific RT activity blocking antibodies, were shown useful for discrimination between RTs from different retrovirus genera. RT activity assay for HIV-1 was found to quantitate different subtypes more equally efficient than p24 antigen assays did.</p><p>Viral load (VL), the amount of HIV particles in the blood, is an important marker of the clinical status of an infected person. A method for VL determination based on RT activity (ExaVir Load) was developed. After plasma pretreatment, to inactivate cellular DNA polymerases, virions in patient plasma were immobilized on a gel, which was washed to remove disturbing factors. The virions were lysed with a detergent containing buffer and the lysate eluted. Finally, the RT activity in the lysate was determined and found to correlate strongly to VL by RNA according to a PCR based standard method (Roche Amplicor 1.5). The second version of the method was able to measure VL down to approximately 400 HIV-1 RNA copies/ml. The usefulness of RT from the VL procedure for determination of susceptibility towards anti-HIV drugs was demonstrated, and the results were in agreement with genotypic data. </p><p>Due to its technical simplicity, and ability to detect a broad range of HIV-1 subtypes, ExaVir Load and the drug susceptibility application are interesting for clinical use, particularly but not only in resource limited settings. The concept is also potentially useful for research purposes, e.g. in combination with specific RT assay conditions.</p>

Viruses are a major threat to humans due to their unique adaptability, evolvability and  capability to control their hosts as parasites and genetic elements. HIV/AIDS is the third largest cause of death by infectious diseases in the world, and drug resistance due to the viral mutations is still the leading cause of treatment failure. The flaviviruses, such as Dengue virus (DEN) and Japanese encephalitis virus (JEV), represent other major cause of morbidity and mortality, and the areas where these viruses are endemic are spreading rapidly. No curative therapy for any flavivirus could be made available as yet. The first part of this thesis focuses on the HIV-1 drug resistance caused by mutations in a major HIV drug target, the HIV-1 reverse transcriptase (RT) as a response to the largest class of clinically used anti-retrovirals, the NRTIs. A robust proteochemometric model was created to analyse the complex mutation patterns in RT drug resistance. The model identified more than ten frequently-occurring mutations, each conferring at least two-fold decrease in susceptibility for one or several NRTIs. Using our prediction server (hivdrc.org), the model can be applied to propose optimum combination therapy for patients harbouring mutated HIV variants. The second part of the thesis encompasses studies on a promising drug target, the NS2B(H)-NS3pro, in two flaviviruses, namely the dengue virus (DEN) and Japanese encephalitis virus (JEV). Functional determinants of DEN NS2B(H)-NS3pro were identified by site-directed mutagenesis. Further, peptide inhibitors were designed using proteochemometrics (PCM) and statistical molecular design (SMD), synthesized and assayed on DEN proteases, which resulted in some novel peptides with low micromolar or sub-micromolar inhibitor activity. The very poorly characterised JEV NS2B(H)-NS3pro  was cloned, purified and the kinetic parameters of this attractive drug target were determined for a series of model substrates and inhibitor. The results identified the role in target-ligand interaction of different residues on specific positions in the target (NS2B(H)-NS3pro) and ligands (substrates/inhibitors). Overall, the findings in this thesis contribute to rational antiviral drug discovery and therapy.